Table of Contents
1 Industry Outlook 10
1.1 Industry Overview 10
1.2 Industry Trends 10
1.3 Total Addressable Market (TAM) 11
2 Report Outline 14
2.1 Report Scope 14
2.2 Report Summary 14
2.3 Research Methodology 15
2.4 Report Assumptions 15
3 Market Snapshot 16
3.1 Market Definition - Infoholic Research 16
3.2 Segmented Addressable Market (SAM) 16
3.2.1 Trends of cardiovascular drugs market 16
3.3 Related Markets 17
3.3.1 Oncology (Cancer) Drugs 17
3.3.2 Active pharmaceutical ingredients (APIs) 18
3.3.3 Over the counter drugs (OTC) 18
3.3.4 Diabetes Drugs 19
4 Market Outline 20
4.1 Cardiovascular Drugs Approved by FDA (2011 - 2016) 20
4.2 Market Segmentation 21
4.3 Porter 5(Five) Forces 22
4.4 PEST Analysis 23
5 Market Characteristics 24
5.1 Market Dynamics 24
5.1.1 Drivers 24
5.1.1.1 Increasing Aging Population 24
5.1.1.2 Increasing prevalence of cardiovascular diseases 26
5.1.1.3 High Prevalence of Obesity 26
5.1.1.4 Unhealthy lifestyle 26
5.1.2 Opportunities 26
5.1.2.1 Increase merger and acquisitions 26
5.1.3 Restraints 27
5.1.3.1 Complex drug development process 27
5.1.3.2 Adverse effects of cardiovascular drugs 27
5.1.4 DRO - Impact Analysis 28
5.1.5 Key Stakeholders 29
6 Product Type: Market Size and Analysis 30
6.1 Overview 30
6.2 Anti-Hypertensives 31
6.3 Anti-Hyperlipidemics 32
6.4 Anti-Coagulants 33
6.5 Anti-Arrhythmic 34
6.6 Others 35
7 Regions: Market Size and Analysis 37
7.1 Overview 37
7.2 North America 39
7.2.1 Overview 39
7.2.2 United States 40
7.2.3 Canada 41
7.3 Europe 41
7.3.1 Overview 41
7.3.2 United Kingdom 42
7.3.3 Germany 43
7.4 APAC 43
7.4.1 Overview 43
7.4.2 India 44
7.4.3 China 44
7.4.4 Japan 45
7.5 Rest of the World 45
7.5.1 Overview 45
7.5.2 Africa 46
7.5.3 Brazil 46
8 Competitive Landscape 48
9 Vendor Profiles 50
9.1 Novartis AG 50
9.1.1 Overview 50
9.1.2 Business Unit 53
9.1.3 Geographic Presence 54
9.1.4 Business Focus 55
9.1.5 SWOT Analysis 55
9.1.6 Business Strategy 56
9.2 Sanofi 57
9.2.1 Overview 57
9.2.2 Geographic Revenue 60
9.2.3 Business Focus 60
9.2.4 SWOT Analysis 61
9.2.5 Business Strategy 61
9.3 Bayer AG 62
9.3.1 Overview 62
9.3.2 Business Unit 64
9.3.3 Geographic Presence 65
9.3.4 Business Focus 65
9.3.5 SWOT Analysis 66
9.3.6 Business Strategy 66
9.4 Johnson & Johnson 66
9.4.1 Overview 66
9.4.2 Business Units 70
9.4.3 Geographic Revenue 71
9.4.4 Business Focus 72
9.4.5 SWOT Analysis 73
9.4.6 Business Strategies 73
9.5 Astra Zenca PLC. 74
9.5.1 Overview 74
9.5.2 Geographic Presence 78
9.5.3 Business Focus 78
9.5.4 SWOT Analysis 78
9.5.5 Business Strategy 79
10 Companies to Watch For 80
10.1 Daiichi Sankyo' Inc. 80
10.1.1 Overview 80
10.1.2 Overview 80
10.2 Bristol-Myers Squibb 81
10.2.1 Overview 81
10.3 GlaxoSmithKline plc 83
10.3.1 Overview 83
10.4 United Therapeutics Corp 85
10.4.1 Overview 85
10.4.2 Highlights 85
10.5 Sun Pharmaceuticals. 86
10.5.1 Overview 86
10.5.2 Highlights 87
10.6 Eli Lilly and Company. 87
10.6.1 Overview 87
10.7 Takeda Pharmaceutical Co' Ltd 88
10.7.1 Overview 88
10.7.2 Highlights: 89
10.8 Boehringer Ingelheim GmbH 89
10.8.1 Overview 89
10.8.2 Highlights: 90
10.9 Gilead Sciences' Inc 90
10.9.1 Overview 90
10.9.2 Highlights: 91
Annexure 91
Abbreviations 91